Lumira Ventures
Founded in Toronto in 2007, Lumira Ventures is a venture capital firm focusing on investments in biotechnology, biopharmaceuticals, medical devices, digital health, and consumer health companies. With offices across North America, the firm invests primarily in Canada and the United States, typically allocating between USD 5 million to USD 15 million per investment. Lumira Ventures actively supports its portfolio companies by facilitating access to funding sources, partners, and market opportunities.
https://crunchbase.com/organization/***
https://linkedin.com/company/***
Past deals in Nova Scotia
IMV
Post in 2020
IMV Inc., headquartered in Dartmouth, Canada, is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies and vaccines against infectious diseases. Founded in 2000, the company utilizes its proprietary delivery platform (DPX) to directly program immune cells within the body, enhancing their ability to target and eliminate specific threats. IMV's lead drug candidate, DPX-Survivac, is a targeted T cell therapy that has shown promising results in late-stage ovarian cancer and relapsed/refractory DLBCL, with multiple Phase 2 clinical trials ongoing across six cancer indications. Additionally, the company is developing a DPX-based vaccine candidate against COVID-19 and DPX-RSV, targeting the respiratory syncytial virus strain A. IMV collaborates with infectious disease experts and has partnerships in the animal health sector, including an agreement with Pfizer Animal Health.
IMV
Post in 2020
IMV Inc., headquartered in Dartmouth, Canada, is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies and vaccines against infectious diseases. Founded in 2000, the company utilizes its proprietary delivery platform (DPX) to directly program immune cells within the body, enhancing their ability to target and eliminate specific threats. IMV's lead drug candidate, DPX-Survivac, is a targeted T cell therapy that has shown promising results in late-stage ovarian cancer and relapsed/refractory DLBCL, with multiple Phase 2 clinical trials ongoing across six cancer indications. Additionally, the company is developing a DPX-based vaccine candidate against COVID-19 and DPX-RSV, targeting the respiratory syncytial virus strain A. IMV collaborates with infectious disease experts and has partnerships in the animal health sector, including an agreement with Pfizer Animal Health.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.